Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Five RNAi-Related Patent Applications: May 11, 2006

Premium

Title: Methods and Materials for Conferring Resistance to Pests and Pathogens of Plants

Number: 20060095987

Filed: Oct. 21, 2005

Inventor: Charles Niblett, Venganza

The patent application, its abstract states, covers "methods and materials for conferring pest resistance to plants. Plants are transformed with a silencing construct homologous to a gene of a plant pest that is essential for the survival, development, or pathogenicity of the pest. This results in the plant producing RNAi to the selected gene, which, when ingested by the pest, results in silencing of the gene and a subsequent reduction of the pest's ability to harm the plant. In other embodiments, the pest's reduced ability to harm the plant is passed on to pest progeny. Methods and materials for de-pathogenesis of pests is also provided," the abstract adds.


Title: Nuclease-Resistant Double-Stranded Ribonucleic Acid

Number: 20060094678

Filed: May 27, 2005

Lead Inventor: Hans-Peter Vornlocher, Alnylam Pharmaceuticals

"This invention relates to modified double-stranded oligoribonucleic acid having improved stability in cells and biological fluids, and methods of making and identifying dsRNA having improved stability, and of using the dsRNA to inhibit the expression or function of a target gene," according to the patent application's abstract.


Title: Compositions and Methods for Treating Cancer Using Compositions Comprising an Inhibitor of Endothelin Receptor Activity

Number: 20060094676

Filed: Oct. 29, 2004

Lead Inventor: Ronit Lahav, Institut Universitaire de Pathologie

"Elevated ETRB activity, BCL-2A1 activity and/or PARP-3 activity was detected in cancer cells, and determined to be associated with growth and proliferation of the cancer cells," the patent application's abstract states. "Accordingly, methods are provided for treating cancer by reducing or inhibiting the ETRB activity, BCL-2A1 activity and/or PARP-3 activity. Also provided are methods of determining the responsiveness of cancer cells to treatment with inhibitors of ETRB activity, BCL-2A1 activity and/or PARP-3 activity. Further, decreased cell viability was observed to correlate with reduction in ETRB expression, and reduction in ETRB protein levels by siRNA led to an increase in cell death."


Title: iRNA Agents Targeting VEGF

Number: 20060094032

Filed: March 11, 2005

Lead Inventor: Antonin de Fougerolles, Alnylam Pharmaceuticals

The features of the invention "relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor, such as by the mechanism of RNA interference," the patent application's abstract states. "The compounds and compositions include iRNA agents that can be unmodified or chemically modified."


Title: Intravascular Delivery of Nucleic Acid

Number: 20060093584

Filed: Nov. 7, 2005

Lead Inventor: Jon Wolff, Mirus Bio

The patent application, its abstract states, claims "a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic acid to an extravascular parenchymal cell."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.